Introduction
The steroid hormones, estrogens and androgens, are key 15 drivers of several types of cancer, such as that of prostate, one of the most common invasive cancer in men. At present, hormone therapies demonstrate success on this type of tumor, highlighting its dependence on gonadal. Although most prostate tumors initially respond to hormone therapy 1 by 20 inhibition of their growth, others stopped respond to the treatment, indicating the need to develop novel therapeutic approches.
Prevoius research 2 has shown that GnRHs (GnRH I and II) and their receptors are expressed in cancer cells and the 25 activation of GnRH receptors negatively regulates their proliferation for instance in prostate cancer. GnRH I is a hypotalamic decapeptide (pGlu 1 -His 2 -Trp 3 -Ser 4 -Tyr 5 -Gly 6 -Leu 7 -Arg 8 -Pro 9 -Gly 10 -NH2, Figure 1 ) able to bind specific receptors on pituitary gonadotrope cells to modulate 30 the synthesis and secretion of gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) 3 that, in turn, regulate gonadal steroidogenesis and gametogenesis. Numerous experimental data showed an overexpression of GnRH I and its receptor in human malignant tumors, such as 35 prostate, breast, uterine, ovarian cancers and also in the nonreproductive ones. In addition to its direct action on cancer cells, GnRH I affect their growth by triggering the secretion of steroid hormones from the gonads. 40 Moreover, the antiproliferative activity of GnRH analogues have been proven through several studies. 3 Furthermore a second form of GnRH (GnRH II, Chart 1) has been identified in humans. 4 It is a decapeptide, encoded by a diverse gene, differing from the classical GnRH (GnRH I, 45 Chart 1) in three amino acids . The ability of GnRH II to inhibit selectively the growth of cancer cells has been recently discovered. 2 This occurs through a different mechanism of action than the classic GnRH agonists one, which involves the suppression of secretion of pituitary hormones and hence 50 production of sex hormones 1 Although GnRH antagonists (which can be considered as a new generation of male and female contraceptives with add-55 back gonadal steroids 3 ) have found increasing application in the therapy of prostate cancer, 5a however recent studies on the activation of the receptors by GnRH agonists also showed a significant reduction of the proliferation of prostate cancer cells both in vitro and in vivo 5b (when inoculated into nude 60 mice). Moreover, GnRH agonists are able to decrease the invasive behavior 6, 7 of androgen-dependent and independent prostate cancer cells, [8] [9] [10] although in this case the administration may be used as an adjuvant therapy. Preliminary experimental data indicate that GnRH agonists increase expression of genes 65 related to apoptosis and develop a cytostatic action rather than cytotoxic.
11 They can sensitize prostate cancer cells to the activity of pro-apoptotic agents, which can be considered as a possible targeted therapy, in combination with traditional chemotherapy, with the aim to increase antiproliferative 70 activity and possibly reduce undesired side-effects . 12 As many hormones of peptidic nature, GnRH I and II are highly flexible molecules, existing in solution as a mixture of different conformers in equilibrium. GnRH is characterized by the presence of a β-turn in position Gly 6 with N-methyl-leucine and the introduction of a lactam bridge, able to force the angles Ψ of Gly 6 and Φ of Leu 7 14 favoring a β-turn conformation. 15 All these modifications resulted to give the maintenance or improvement of biological 80 activity. 16 Schematic representation of GnRH I in the folded conformation in which it is bound to the GnRH pituitary receptor.
Since the β-turn present in the GnRH-I and II seems to be essential for the biological activity of these hormones, a large 15 number of cyclic peptides related to GnRH-I have been designed to maintain this property. The replacement of the glycine residue at position 6 has been shown to stabilize of the folded conformation and decreases the metabolic clearance. 17 All the analogues, agonists and antagonists, have been synthesized with this structural 55 modification (for instance, among the agonists, Leuprolide has a D-Leu residue, 8a while Goreselin a D-Ser 18-20 at position 6). In order to identify new potential peptidomimetic analogues of GnRH, with potential biological activity, we focused our attention on the synthesis of two novel series (I and II, GnRH 60 I and GnRH II analogues, respectively) by SPPS methodology.
21, 22 We considered the introduction of non natural amino acids at position 6, such as those with cycled structures, which are known to favour the interaction between the receptor and the ligand, because of their β-turn inducer 65 nature (I-II a-e, Table 1 ). Of note, the steric hindrance and the minor peptidic character of the novel analogues could reduce the metabolic cleavage, occurring at position 6-7, and increase their biological half-life. [23] [24] 70 Table 1 . GnRH I and II analogues I-II a-e.
Furthermore in attempt to improve the metabolic stability, few other derivatives (Table 2) The first amino acid Glycine was attached to the resin by the C-terminal end, while the N-terminal end was deprotected before the following coupling. After the complete synthesis, the peptide was washed with DCM and cleaved with TFA and a scavenger cocktail. The The N-terminus residue was protected as ACE (acetyl), while the C-terminus as NME (N-methyl). All the calculations were carried out using the SANDER module of the AMBER 10 package 25 along with the ff03 force field for 1 and the general amber force field (gaff) for D-Ic,
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D-Id, D-Ie and RESP atomic charges. The TIP3P model 26 was employed to explicitely represent water molecules. The polypeptides were immersed in a box containing about 1300 water molecules. At first, the energy of the water molecules was minimized, keeping the atoms of the polypeptides frozen.
This journal is © The Royal Society of Chemistry [year] Then, a minimization of the whole system was performed by setting a convergence criterion on the gradient of 10 -4 kcal mol -1 Å -1 . Prior to starting the MD simulations, the system was equilibrated for 40 ps at 300 K in isocore conditions (NVT). Subsequently, 5 ns of MD simulations in isothermal-60 isobaric ensemble were carried out at 300 K with a 2 fs timestep (NPT). In the production runs, the systems were performed in periodic boundary conditions. Van der Waals and short-range electrostatic interactions were estimated within a 8 Å cutoff. SHAKE algorithm 27 was applied to all bonds involving 65 hydrogen atoms. VMD 1.8.7 was used for molecular visualization and for animating trajectory data. 
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Particular attention was focussed on the possibility of -turn formation. In fact, it is known that the presence of a -turn in position Gly 6 -Leu 7 of GnRH I is essential for biological activity. During the MD simulation, in the case of 1, the 95 presence of two -turns, already known in literature was detected: the first one between Tyr and Arg, the second one between Ser and Leu. 23 Previous structure-function studies showed that the substitution of Tyr to eliminate the postulated -II turn with Arg led to a reduction in the binding affinity, 100 while the substitution of Leu to remove the envisaged H bond between the C=O of Ser and the NH of Leu did not reduce activity. So, MD trajectories were examined in order to assess the maintenance of these turns and the distances d1 between C(Tyr)-N(Arg) and d2 between C(Ser)-N(Leu). In Figure 3 
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The different conformational preferences of D-Ic, and, in particular, the complete lack of the -turn between Ser-Leu, present in all the other peptides, seem to explain the synthetic difficulties found to bind the last monomer to its polypeptidic chain. More precisely, the absence of the second β-turn is 5 supposed to lead to an unfavourable orientation of the peptidic chain for introducing the N-terminal amino acid. Moreover, the MD simulations show that the peptidomimetic D-Ie presents the most similar behavior to the reference. Compounds I a,b,d-g, D Since GnRH II binds the human type I GnRH receptor mediating the antiproliferative activity 2 , compound IIe was choosen as reference for a colorimetric MTT assay. The latter is based on the ability of living cells to reduce the yellow MTT to purple formazan and it is widely used to quantitate cell viability and cytotoxicity of various drugs. The results indicate that similar to Leuprolide, the compound 5 IIe decreased the growth of HEK 293 cells expressing the type I GnRH receptor (Figure 6 ). However, the antiproliferative efficacy of compound IIe (as determined by its absorbance ratio versus the control) was smaller than that of Leuprolide (Figure 6 ), in agreement with the ability of this compound to bind to type I GnRH receptor 10 although with a smaller affinity than that of Leuprolide ( Figure 5 ). 
Biological evaluation

Metabolic stability
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To evaluate the metabolic stability of GnRH I, GnRH II and their analogues Ie and IIe, that show the most interesting biological results, a preliminary assay using rat plasma was performed. The results (Figure 7) showed that in compounds Ie and IIe the substitution of Gly6 with the non natural amino acid AC6C-OH 50 results to improve their stability by 15-20 % after four hours when compared to GnRH I and GnRH II, respectively. In particular, product Ie showed a significant increase of half life time with respect to GnRHI (Ie t1/2= 3.96 h versus GnRHI t1/2 = 2.63 h) (For further detail see ESI). The synthesized products were tested in binding assays on human type I GnRH receptor. Compounds Id-f and IIc-e exhibited considerable binding affinities, supporting the assumption that the introduction of β-turn inducers in GnRH I and II structures were essential for the binding to GnRH receptor and confirming the 80 fundamental role of the β-turn presence for the activity. Biological data showed that compounds I-IIe may be considered the most active in their series (I and II respectively), giving experimental support to the modeling hypothesis.
Finally, preliminary metabolic stability assays revealed that the two derivatives Ie and IIe were more stable than GnRH I and GnRH II, due to their reduced peptidic character. These results will be useful for the development of novel GnRH analogues with improved stabilities and antiproliferative activities.
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Experimental Part Chemistry
Resin, Fmoc amino-acids, solvents and reagents were purchased from IRIS Biotech GmbH (Schnelldorf, Germany) and were used without further purification. The peptides were synthesized 10 manually using polypropylene syringes (10 mL) with a porous polyethylene disc purchased from Grace. The analytical HPLC was performed using apparatus Elite La Chrome. The preparative HPLC was performed using apparatus Waters 3000 System Controller. The spectra of high-resolution ESI-MS were recorded 15 using a mass spectrometer LTQ-Orbitrap XL.
General procedure. The synthesis of peptides was performed on solid phase starting from 290 mg of Rink amide resin (130 mmol, loading: 0.46 mmol /g).
Swelling.
Resin was weighted in a test tube. N-methylpyrrolidone 20 (NMP, 1 mL for 130 mmol of resin) and dichloromethane (DCM, 2 mL) were added. The suspension was allowed to sonicate for 2-3 minutes and then poured into the reactor, washing the tube with DCM in order to recover the resin. The liquid was filtered to obtain the dry resin. 25 The Fmoc-protected Rink-amide resin was treated with 20 % piperidine in DMF for 5 minutes, then the solution was filtered and the resin was treated again with 20% piperidine in DMF for 15 minutes. After the solution was filtered, the resin was washed 6 times with DMF.
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Coupling. The Fmoc-amino acid (4 equivalents) and non-natural amino acids were dissolved in a solution of TBTU / HOBt (0.45 M in DMF, 4 eq.) Then N,N-diisopropylethylamine (DIEA, 8 eq.) was added. The solution was poured into the reactor containing the resin and the reaction mixture was left under stirring for 50 35 minutes, after which the solution was filtered and the resin washed with DMF (6 times). Fmoc-Cptd was dissolved in a solution of HATU (0.45 M in DMF, 4 eq.) and the followed procedure was identical to that described above. Standard conditions: 130 mmol of resin, 500 mmol Fmoc-aa, 500 mmol Peptide purification. The peptides were purified by preparative 65 reverse phase HPLC using an appropriate gradient of eluents A and B (see above) with a flow of 14 mL/min, and the detection was performed at 230 and 280 nm. The purified peptide fractions were concentrated under vacuum and to the acqueous was added a drop of 1M HCl. The purified peptides were finally freeze-70 dried. Each final product was checked for purity by analytical HPLC (C18 column) using the following gradient: 0-14 min from 100 % A to 70 % B (flow 1.0 mL/min). The survey was carried out at 230 and 280 nm. and IIa-g were synthesized by coupling of Fmoc-Gly-OH (4 eq., 150 mg) to Rink amide resin (203 mg, 0.64 mmol/g) using TBTU /HOBT (4 eq., 1.1 mL, 0.45 M DMF) and DIEA (10 eq., 170 µL). The products were obtained following the general procedures for synthesis, cleavage and folding described above. 80 the whole system was performed by setting a convergence criterion on the gradient of 10 -4 kcal mol -1 Å -1 . Prior to starting the MD simulations, the system was equilibrated for 40 ps at 300 K in isocore conditions (NVT). Subsequently, 5 ns of MD simulations in isothermal-isobaric ensemble were carried out at 5 300 K with a 2 fs time-step (NPT). In the production runs, the systems were performed in periodic boundary conditions. Van der Waals and short-range electrostatic interactions were estimated within a 8 Å cutoff. SHAKE algorithm 25 was applied to all bonds involving hydrogen atoms. VMD 1.8.7 was used for 10 molecular visualization and for animating trajectory data.
Synthesis of peptides
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Binding Studies
The binding experiments were performed using as radioligand the [
125 I]-DTyr 6 -His 5 -GnRH and membrane homogenates from human embryonic kidney 293 (HEK 293) cells stably expressing 15 the GnRH receptor, which were prepared as previously described. 29 Radioiodination of DTyr 6 -His 5 -GnRH was performed according to the method of Laimou et al. [ 125 I]-DTyr 6 -His 5 -GnRH (100,000-120,000 cpm) was added into membrane homogenates and the mixtures were incubated as previously 20 described. 29 Briefly, aliquots of diluted membrane suspensions (50 μL) and radioligand were added into tubes containing buffer B (25 mM HEPES containing 1 mM CaCl2, 10 mM MgCl2, 0.5% BSA, pH 7.4 at 4 o C) with or without GnRH-analogues at the single concentration of 500 nM or with increasing concentrations (DMEM/F-12) containing 3.15 g/L glucose and 10% bovine calf serum at 37°C and 5% CO2. The cells were plated in 96 well plates at a density of 2000-2500 cells/well and the plates were incubated at 37°C and 5% CO2 for 16 hours. At the end of the incubation, the medium was replaced by DMEM/F-12, containing 50 3.15 g/L glucose and 5% bovine calf serum, and the cells were incubated in a total volume of 100 μL, in the absence (untreated cells) or presence of 1μM Leuprolide or 1μM compound IIe, at 37°C and 5% CO2. Controls included both wells with untreated cells (control) and wells containing only medium (control-blank). 55 The medium with or without peptides was changed every 24 h. After 4 days of treatment, the medium was replaced with a fresh one without peptides and containing 0.5 mg/mL MTT and the plates were incubated for 4 hours at 37°C and 5% CO2. At the end of the incubation 100 μL of dimethyl sulfoxide (DMSO) was 60 added to each well to dissolve the insoluble purple MTT-derived formazan crystals into a colored solution. After 1 hour incubation at 37°C, the absorbance values at 595 nm were determined on a Bio-Rad Elisa microplate reader. The experiments were repeated twice in quadruplicates.
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Metabolic stability studies A solution of the peptide 100 µM in was prepared; then sample extraction was performed by adding 90µL of rat plasma to 10 µL of the solution 100 µM, vortexing and incubating at 37.4°C for respectively 0 minutes, 30 minutes, 70 60 minutes, 4 hours and 24 hours. The proteins were precipitated by addition of 100 µL of a solution of perchloric acid 0.1 M; samples were left at 0°C for 10 minutes and centrifugated at 1400 rpm for 10 minutes; to 180 µL of surnatant 180 µL of mobile phase were added; the solution is filtered into the analysis vial. using the corresponding MRM transitions for each analyte, the peak areas for GnRH I, GnRH II, (peptide concentration of 500 ng/mL) at t = 0 were set as 100 %. Those peak areas were compared to the peak areas derived from samples at t = 30 min, 1 h, 4 h, 24 h. In addition, analysis of blank samples confirmed the 105 absence of interference and established the selectivity of the assay. The experimental data were analyzed by the exponential decay regression model, using GraphPad Prism 4.0 (GraphPad Software, San Diego, CA) and the t1/2 values were obtained (ESI). 
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